Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy

doi:10.16352/j.issn.1001-6325.2023.07.1167

Abstract

Abstract: MicroRNAs(miRNAs) are a class of non-coding RNAs associated with a variety of cardiovascular diseases, including hypertension, heart failure and myocardial infarction. Expression of miRNAs changes during cardiac hypertrophy, which regulates cardiac hypertrophy by regulating cardiomyocyte autophagy, inflammatory response and energy metabolism. This article reviews the expression changes, potential targets and molecular mechanisms of miRNAs in cardiac hypertrophy.

Key words: cardiac hypertrophy, microRNA, target of action, signal pathway

CLC Number:

WANG Fan, DENG Yongzhi. Advances on the role and molecular mechanism of microRNAs in cardiac hypertrophy[J]. Basic & Clinical Medicine, 2023, 43(7): 1167-1170.

References

[1] 《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究,2021, 19: 582-590.
[2] Colpaert RMW, Calore M. MicroRNAs in cardiac diseases[J]. Cells, 2019, 18, 8: 737.doi:10.3390/cells8070737.
[3] Tu YF, Wan L, Bu LH, et al. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention[J]. Cell Physiol Biochem, 2013, 31: 997-1008.
[4] Yang XY, Tao LH, Zhu J, et al. Long noncoding RNA FTX reduces hypertrophy of neonatal mouse cardiac myocytes and regulates the PTEN/PI3K/Akt signaling pathway by sponging microRNA-22[J]. Med Sci Monit, 2019, 25: 9609-9617.
[5] Kopechek JA, McTiernan CF, Chen X, et al. Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function[J]. Theranostics, 2019, 9: 7088-7098.
[6] Yang JJ, Nie Y, Wang F, et al. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy[J]. Biochim Biophys Acta, 2013, 1831: 1386-1394.
[7] Yang J, Xu J, Han X, et al. Lysophosphatidic acid is associated with cardiac dysfunction and hypertrophy by suppressing autophagy via the LPA3/AKT/mTOR pathway[J].Front Physiol, 2018, 9:1315.doi:10.3389/fphys.2018.01315.
[8] Li Z, Song Y, Liu L, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation[J]. Cell Death Differ, 2017, 24: 1205-1213.
[9] Yan HL, Wang H, Zhu XX, et al. PGC-1alphaAdeno-associated virus-mediated delivery of anti-miR-199a tough decoys attenuates cardiac hypertrophy by targeting[J]. Mol Ther Nucleic Acids, 2021, 23: 406-417.
[10] Duygu B, Poels EM, Juni R, et al. miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction[J]. Noncoding RNA Res, 2017, 2: 18-26.
[11] Zhou Y, Li KS, Liu L, et al. MicroRNA132 promotes oxidative stressinduced pyroptosis by targeting sirtuin 1 in myocardial ischaemiareperfusion injury[J].Int J Mol Med, 2020, 45:1942-1950.
[12] Man AWC, Li H, Xia N.The role of sirtuin1 in regulat-ing endothelial function, arterial remodeling and vascular aging[J].Front Physiol, 2019, 10:1173.doi:10.3389/fphys.2018.01315.
[13] Li F, Li SS, Chen H, et al. miR-320 accelerates chronic heart failure with cardiac fibrosis through activation of the IL6/STAT3 axis[J]. Aging (Albany NY), 2021, 13: 22516-22527.
[14] Jia GZ, Liang CG, Li WH, et al. miR-410-3p facilitates Angiotensin Ⅱ-induced cardiac hypertrophy by targeting Smad7[J]. Bioengineered, 2022, 13: 119-127.
[15] Shi JY, Chen C, Xu X, et al. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN/AKT/mTOR signalling pathway and suppressing autophagy[J]. Acta Physiol (Oxf), 2019, 227: 13323.doi:10.1111/apha.13323.
[16] Kura B, Kalocayova B, LeBaron TW, et al. Regulation of microRNAs by molecular hydrogen contributes to the prevention of radiation-induced damage in the rat myocardium[J]. Mol Cell Biochem, 2019, 457: 61-72.
[17] He R, Ding C, Yin P et al. miR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1.[J].Exp Cell Res, 2019, 378: 87-97.
[18] Zhao L, Li W, Zhao H.Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p.[J]. Am J Transl Res, 2020, 12: 718-730.
[19] Yuan Y, Wang J, Chen QX, et al. Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865: 1421-1427.
[20] Long YD, Wang L, Li ZQ.SP1-induced SNHG14 aggravates hypertrophic response in in vitro model of cardiac hypertrophy via up-regulation of PCDH17.[J].J Cell Mol Med, 2020, 24: 7115-7126.
[21] Salamon I, Biagini E, Kunderfranco P, et al. Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson-Fabry disease[J]. Cell Death Dis, 2021, 12: 1150.doi:10.1038/s41419-021-04438-5.
[22] Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, et al. A novel circulating microRNA for the detection of acute myocarditis[J]. N Engl J Med, 2021, 384: 2014-2027.
[23] Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study[J]. Eur Heart J, 2021, 42: 178-188.